Download now Free registration required
Biotechnologically produced drugs, so called biologics, are a major growth driver for the global pharmaceutical market. In 2007 the biologics market grew noticeably faster than the overall market; with a double-digit growth of 20% they generated $95 bn of sales amounting to approximately 15% of global Pharma revenues. The challenge for the development of biosimilars arises from the fact that biologics are more complex than small molecule and chemically synthesized drugs; therefore their replica are - in contrast to 'Traditional' small-molecule generics - "Similar" but not identical to the original drug.
- Format: PDF
- Size: 508.9 KB